

ASPEN PHARMACARE HOLDINGS LIMITED  
(Incorporated in the Republic of South Africa) (“Aspen Holdings”)  
Registration number: 1985/002935/06  
Share code: APN  
ISIN: ZAE000066692  
LEI: 635400ZYSN1IRD5QWQ94  
and its subsidiaries (collectively “Aspen” or “the Group”)

## **ASPEN SECURES DISTRIBUTION RIGHTS IN SOUTH AFRICA FROM AMGEN**

Aspen is pleased to announce that it has concluded an agreement with Amgen, in terms of which Aspen will exclusively market, distribute, use, and sell Amgen’s products in South Africa (the Territory) for an initial term of 5 years, which will be renewed. Amgen is a biotechnology pioneer whose medicines reach millions of seriously ill patients around the world. Amgen’s products include Aranesp®, Amgevita®, Prolia®, Repatha®, NPlate®, Vectibix® and Blincyto®.

Amgen will continue to manufacture and supply its products to Aspen for the duration of the contract.

The Transaction includes future pipeline products and an opportunity for expansion of the Territory into the rest of Sub-Saharan Africa.

The Transaction will complete by 01 July 2023.

The Transaction forms part of Aspen’s strategy to be a partner of choice to leading global pharmaceutical and biotechnology companies for niche products in emerging markets. Amgen focuses on areas of high unmet medical need and has a robust pipeline including biosimilars that will be registered and/or submitted for registration in the near future. At present, Aspen is not represented in these therapeutic areas with high growth potential.

Durban  
04 May 2023

**Sponsor**  
**Investec Bank Limited**